7506 ORAL Up to 6 years follow-up of patients receiving imatinib mesylate (Glivec) to treat unresectable or metastatic gastrointestinal stromal tumors (GISTs)

✍ Scribed by Joensuu, H.; Demetri, G.D.; Heinrich, M.C.; Eisenberg, B.L.; Fletcher, J.A.; Corless, C.L.; Fletcher, C.D.; Blanke, C.; Heintz, D.; von Mehren, M.

• Book ID: 122578115
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 60 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(07)71483-0